Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients with Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-existing Liver and/or Renal Dysfunction

BACKGROUND: The safety and efficacy of frontline nilotinib and dasatinib in newly diagnosed chronic-phase chronic myelogenous leukemia (CML-CP) patients with pre-existing liver and/or renal dysfunction are unknown. PATIENTS AND METHODS: We analyzed adverse event rates, response rates, and survival r...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Lymphoma Myeloma Leuk
Main Authors: Sasaki, Koji, Lahoti, Amit, Jabbour, Elias, Jain, Preetesh, Pierce, Sherry, Borthakur, Gautam, Daver, Naval, Kadia, Tapan, Pemmaraju, Naveen, Ferrajoli, Alessandra, O’Brien, Susan, Kantarjian, Hagop, Cortes, Jorge
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4769134/
https://ncbi.nlm.nih.gov/pubmed/26796981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2015.12.003
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares